2730
Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women with osteoporosis.
 ( potential therapeutic event: treat ,  postmenopausal women with osteoporosis: Subject, osteoporosis: Subject.Disorder, increase bone mineral density (BMD): Effect, decrease biochemical markers of bone turnover: Effect, Both raloxifene (RLX) and alendronate (ALN): Treatment, vertebral fractures: Treatment.Disorder, raloxifene: Treatment.Drug, alendronate: Treatment.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: treat ,  postmenopausal women with osteoporosis: Subject, osteoporosis: Subject.Disorder, increase bone mineral density (BMD): Effect, decrease biochemical markers of bone turnover: Effect, Both raloxifene (RLX) and alendronate (ALN): Treatment, vertebral fractures: Treatment.Disorder, raloxifene: Treatment.Drug, alendronate: Treatment.Drug) 